Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Daiichi Sankyo has entered into an agreement with the Kyorin Holdings, a subsidiary of Kyorin Pharmaceutical for the development and marketing of Imidafenacin used to treat overactive bladder (OAB).
Subscribe to our email newsletter
Kyorin Pharmaceutical has discovered and developed Imidafenacin.
Kyorin Pharmaceutical grants Daiichi Sankyo rights to activities related to the development and marketing of Imidafenacin in Brazil, as per the agreement.
Imidafenacin is a anticholinergic agent that acts as a selective antagonist on M3 and M1 muscarinic subtype receptors to improve the urgency of urination, pollakiuria and urge urinary incontinence associated with OAB.